Follow-On Biologics Bill Clears Senate Cmte. With Stronger Language On Exclusivity Cap
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic firms remain concerned that innovators would be able to "evergreen" their products through minor changes.